Advertisement

Hormone Replacement Therapy and Breast and Gynecologic Cancers

  • P. Sismondi
  • N. Biglia
  • M. Giai
  • R. Ponzone
  • C. Campagnoli
Part of the Medical Science Symposia Series book series (MSSS, volume 11)

Abstract

The most serious obstacle to the diffusion of hormone replacement therapy (HRT) in menopause is the concern that HRT, either estrogens alone or combined with progestins, may enhance morbidity and mortality due to the development of malignant neoplasia in reproductive organs, particular breast and endometrial cancer. We reviewed the literature on breast and gynecological cancer risk for HRT users, specifically addressing the issues of duration, dose, and type of hormonal compounds in influencing cancer risk.

Keywords

Breast Cancer Ovarian Cancer Breast Cancer Risk Endometrial Cancer Hormone Replacement Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cline JM, Soderqwist G, von Schoultz E, et al. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996;174:93–100.PubMedCrossRefGoogle Scholar
  2. 2.
    Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1985;87:190–97.CrossRefGoogle Scholar
  3. 3.
    Armstrong B. Oestrogen therapy after the menopause-boon or bane? Med J Aust 1988;148:213–14.PubMedGoogle Scholar
  4. 4.
    Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1988;151:67–72.CrossRefGoogle Scholar
  5. 5.
    Steinberg KK, Thacker SB, Smith S J, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016–37.PubMedGoogle Scholar
  7. 7.
    Sillero-Arenas M, Delgado-Rodriguez M, Rodriguez-Canteras R, Bueno-Cavanillas A, Galvez-Vergas R. Menopausal hormone replacement therapy and breast cancer: A metaanalysis. Obstet Gynecol 1992;79:286–94.PubMedGoogle Scholar
  8. 8.
    Colditz GA, Egan KM, Stampfer MJ, et al. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993; 168:1473–80.PubMedGoogle Scholar
  9. 9.
    Colditz GA, Hankinson SE Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. NEJM 1995;332:1589–93.PubMedCrossRefGoogle Scholar
  10. 10.
    La Vecchia C, Negri E, Franceschi S, et al. Hormone replacement treatment and breast cancer risk: A cooperative Italian study. Br J Cancer 1995;72:244–48.PubMedCrossRefGoogle Scholar
  11. 11.
    Stanford J, Weiss N, Voigt L, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Newcomb PA, Longnecker MP, Storer BE, et al. Long term hormone replacement therapy and risk of breast cancer in post menopausal women. Am J Epidemiol 1995; 142:788–95.PubMedGoogle Scholar
  13. 13.
    Schunrmans A, Van den Brandt P, Goldbohm R. Exogenous hormone use and the risk of postmenopausal breast cancer: Results from the Netherlands cohort study. Cancer Causes Contr 1995;6:416–24.CrossRefGoogle Scholar
  14. 14.
    Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy — long-term follow-up of a Swedish cohort. Int J Cancer 1996;67(3):327–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Kennedy DL, Baum C, Forbes MB. Non-contraceptive estrogens and progestins: Use patterns overtime. Obstet Gynecol 1985;65:441.PubMedGoogle Scholar
  16. 16.
    Weissemberger AJ, Ho KKY, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insuline-like growth factor I, and GH binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374–81.CrossRefGoogle Scholar
  17. 17.
    Campagnoli C, Biglia N, Peris C, Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol 1995;9:67–74.PubMedCrossRefGoogle Scholar
  18. 18.
    Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor I, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993;7:251–58.PubMedCrossRefGoogle Scholar
  19. 19.
    Staffa JA, Newschaffer CJ, Jones JK, Miller V. Progestins and breast cancer: An epidemiologic review. Fertil Steril 1992;57:473–91.PubMedGoogle Scholar
  20. 20.
    Sitruk-Ware R. Estrogens, progestins and breast cancer risk in post-menopausal women: State of the ongoing controversy in 1992. Maturitas 1992;15:129–39.PubMedCrossRefGoogle Scholar
  21. 21.
    Palmer JL, Rosenberg L, Clarke EA, et al. Breast cancer risk after estrogen replacement therapy: Result from the Toronto breast cancer study. Am JEpidemiol 1991;134:1386.Google Scholar
  22. 22.
    Natchtigall MJ, Smilen SW, Nachtigall RD, et al. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992;80:827–30.Google Scholar
  23. 23.
    Gambrell R, Maier RC, Sanders BI, et al. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435–43.PubMedGoogle Scholar
  24. 24.
    Bergkvist L, Adami HO, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. NEJM 1989;321:293–97.PubMedCrossRefGoogle Scholar
  25. 25.
    Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42:832–38.PubMedCrossRefGoogle Scholar
  26. 26.
    Colditz GA, Stampfer MJ, Willet WC, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses’ Health Study. Cancer Causes Control 1992;3:433–39.PubMedCrossRefGoogle Scholar
  27. 27.
    Bergkvist L, Adami HO, Person I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am JEpidemiol 1989;130:221–28.Google Scholar
  28. 28.
    Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement. Arch Intern Med 1991;151:75–78.PubMedCrossRefGoogle Scholar
  29. 29.
    Bonnier P, Romain S, Giacalone PL, et al. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85(1):11–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Potischman N, Hoover M, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. JNCI 1996;88(16): 1127–35.PubMedCrossRefGoogle Scholar
  31. 31.
    Grady D, Gebretsadik T, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304–13.PubMedCrossRefGoogle Scholar
  32. 32.
    Hammond C, Jelovsek F, Lee K, et al. Effects of long-term estrogen replacement therapy. II Neoplasia. Am J Obstet Gynecol 1979;133:537–47.PubMedGoogle Scholar
  33. 33.
    Nachtigall L, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Voigt L, Weiss N, Chu J, et al. Progestogen supplementation of exogenous estrogens and risk of endometrial cancer. Lancet 1991;338:274–77.PubMedCrossRefGoogle Scholar
  35. 35.
    Jick S, Walker A, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993;4:20–24.PubMedCrossRefGoogle Scholar
  36. 36.
    Brinton L, Hoover R. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues. Obstet Gynecol 1993;81:265–71.PubMedGoogle Scholar
  37. 37.
    Gambrell R Jr, Massey F, Castaneda T, et al. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732–38.PubMedGoogle Scholar
  38. 38.
    Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogehs alone or in conjunction with progestogens: Results of a prospective study. BMY 1989;298:147–51.CrossRefGoogle Scholar
  39. 39.
    The Writing Group for the PEPI Trial. Effects of HRT on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;275(5):370–75.CrossRefGoogle Scholar
  40. 40.
    Gibbons WE, Moyer DL, Lobo RA, et al. Biochemical and histology effects of sequential estrogeti/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol 1986;154:456–61.PubMedGoogle Scholar
  41. 41.
    Woordruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxy-progesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol. 1994;170:1213–23.Google Scholar
  42. 42.
    Cerin Heldas K, Moeller B. Adverse endometrial effects of long cycle estrogen and progestogen replacement therapy. New Eng J Med 1996;334:668–69.PubMedCrossRefGoogle Scholar
  43. 43.
    Whittemore AS, Harris R, Intyre J. Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. Am J Epidemiol 1992;136:1184–1203.PubMedGoogle Scholar
  44. 44.
    Thomas DB. Estrogen replacement therapy and cancer: Endometrial, breast and ovarian. In: Kerenman SG, editor. Proceedings of the Symposium on The Menopause, Napa CA, March 1989, Serono Symposia 1990; 101–21.Google Scholar
  45. 45.
    Hildreth NG, Kelsey JL, Li Volsi VA, et al. An epidemiologic study on epithelial carcinoma of the ovary. Am J Epidemiol 1981;114:398–405.PubMedGoogle Scholar
  46. 46.
    Wu ML, Whittemore AS, Paffenbarger RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. Am J Epidemiol 1988; 128:1216–27.PubMedGoogle Scholar
  47. 47.
    Purdie D, Green A, Bain C, et al. Reproductive and other factors and risk of epithelial ovarian cancer: An Australian case-control study. Int J Cancer 1995;62:678–84.PubMedCrossRefGoogle Scholar
  48. 48.
    Hartge P, Hoover R, McGowan L, et al. Menopause and ovarian cancer Am J Epidemiol 1988;127:990–98.PubMedGoogle Scholar
  49. 49.
    Smith EM, Sowers MF, Burns TL. Effects of smoking on the development of female reproductive cancers. JNCI 1984;73:371–76.PubMedGoogle Scholar
  50. 50.
    Cramer DW, Hutchinson GB, Welch WR, et al. Determinants of ovarian cancer risk. 1: Reproductive experiences and family history. JNCI 1983;71:711–16.PubMedGoogle Scholar
  51. 51.
    Booth M, Berai V, Smith P. Risk factor for ovarian cancer: A case-control study. Br J Cancer 1989;60:592–98.PubMedCrossRefGoogle Scholar
  52. 52.
    Polychronopoulou A, Tzonou A, Hsieh C, et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 1993;55:402–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Kaufman DW, Kelly JP, Welch WR, et al. Non-contraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989;130:1142–51.PubMedGoogle Scholar
  54. 54.
    Parazzini F, La Vecchia C, Negri E, et al. Estrogen replacement therapy and ovarian cancer. Int J Cancer 1994;57:135–36.PubMedCrossRefGoogle Scholar
  55. 55.
    Rodriguez C, Calle E, Coates RJ, et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995;141:823–35.Google Scholar
  56. 56.
    Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving HRT. Br J Obstet Gynecol 1987;94:620–35.CrossRefGoogle Scholar
  57. 57.
    Newcomb PA, Weiss NS, Daling JR. Incidence of vulvar carcinoma in relation to menstrual, reproductive and medical factors. JNCI 1984;73:391–96.PubMedGoogle Scholar
  58. 58.
    Brinton LA, Nasca PC, Mallin K, et al. Case-control study of cancer of the vulva. Obstet Gynecol 1990;75:859–66.PubMedGoogle Scholar
  59. 59.
    Sherman KJ, Daling JR, McKnight B, Chu J. Hormonal factors in vulvar cancer. A case-control study. J Reprod Med 1994;39:857–61.PubMedGoogle Scholar
  60. 60.
    Weiss N, Hill D. Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Maturitas 1996;23:235–39.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1997

Authors and Affiliations

  • P. Sismondi
  • N. Biglia
  • M. Giai
  • R. Ponzone
  • C. Campagnoli

There are no affiliations available

Personalised recommendations